Takeda Pharmaceutical Statistics
Total Valuation
Takeda Pharmaceutical has a market cap or net worth of $57.17 billion. The enterprise value is $88.09 billion.
Important Dates
The last earnings date was Thursday, January 29, 2026, before market open.
| Earnings Date | Jan 29, 2026 |
| Ex-Dividend Date | Sep 30, 2025 |
Share Statistics
Takeda Pharmaceutical has 1.58 billion shares outstanding. The number of shares has increased by 0.25% in one year.
| Current Share Class | n/a |
| Shares Outstanding | 1.58B |
| Shares Change (YoY) | +0.25% |
| Shares Change (QoQ) | +1.77% |
| Owned by Insiders (%) | 0.07% |
| Owned by Institutions (%) | 46.42% |
| Float | 1.58B |
Valuation Ratios
The trailing PE ratio is 79.37 and the forward PE ratio is 29.49.
| PE Ratio | 79.37 |
| Forward PE | 29.49 |
| PS Ratio | 2.01 |
| Forward PS | 0.02 |
| PB Ratio | 1.17 |
| P/TBV Ratio | n/a |
| P/FCF Ratio | 8.66 |
| P/OCF Ratio | 7.54 |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
The stock's EV/EBITDA ratio is 10.84, with an EV/FCF ratio of 13.35.
| EV / Earnings | 122.30 |
| EV / Sales | 3.09 |
| EV / EBITDA | 10.84 |
| EV / EBIT | 22.90 |
| EV / FCF | 13.35 |
Financial Position
The company has a current ratio of 1.19, with a Debt / Equity ratio of 0.71.
| Current Ratio | 1.19 |
| Quick Ratio | 0.54 |
| Debt / Equity | 0.71 |
| Debt / EBITDA | 4.09 |
| Debt / FCF | 5.24 |
| Interest Coverage | 4.62 |
Financial Efficiency
Return on equity (ROE) is 1.50% and return on invested capital (ROIC) is 2.76%.
| Return on Equity (ROE) | 1.50% |
| Return on Assets (ROA) | 2.47% |
| Return on Invested Capital (ROIC) | 2.76% |
| Return on Capital Employed (ROCE) | 4.71% |
| Weighted Average Cost of Capital (WACC) | 3.42% |
| Revenue Per Employee | $600,047 |
| Profits Per Employee | $15,177 |
| Employee Count | 47,455 |
| Asset Turnover | 0.29 |
| Inventory Turnover | 1.16 |
Taxes
In the past 12 months, Takeda Pharmaceutical has paid $587.95 million in taxes.
| Income Tax | 587.95M |
| Effective Tax Rate | 44.89% |
Stock Price Statistics
The stock price has increased by +36.11% in the last 52 weeks. The beta is 0.08, so Takeda Pharmaceutical's price volatility has been lower than the market average.
| Beta (5Y) | 0.08 |
| 52-Week Price Change | +36.11% |
| 50-Day Moving Average | 15.87 |
| 200-Day Moving Average | 14.93 |
| Relative Strength Index (RSI) | 78.32 |
| Average Volume (20 Days) | 3,594,983 |
Short Selling Information
The latest short interest is 9.83 million, so 0.62% of the outstanding shares have been sold short.
| Short Interest | 9.83M |
| Short Previous Month | 11.65M |
| Short % of Shares Out | 0.62% |
| Short % of Float | 0.62% |
| Short Ratio (days to cover) | 3.78 |
Income Statement
In the last 12 months, Takeda Pharmaceutical had revenue of $28.48 billion and earned $720.25 million in profits. Earnings per share was $0.45.
| Revenue | 28.48B |
| Gross Profit | 18.66B |
| Operating Income | 3.85B |
| Pretax Income | 1.31B |
| Net Income | 720.25M |
| EBITDA | 8.13B |
| EBIT | 3.85B |
| Earnings Per Share (EPS) | $0.45 |
Full Income StatementBalance Sheet
The company has $4.18 billion in cash and $34.58 billion in debt, with a net cash position of -$30.40 billion or -$19.25 per share.
| Cash & Cash Equivalents | 4.18B |
| Total Debt | 34.58B |
| Net Cash | -30.40B |
| Net Cash Per Share | -$19.25 |
| Equity (Book Value) | 48.75B |
| Book Value Per Share | 30.86 |
| Working Capital | 3.23B |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was $7.58 billion and capital expenditures -$1.14 billion, giving a free cash flow of $6.60 billion.
| Operating Cash Flow | 7.58B |
| Capital Expenditures | -1.14B |
| Free Cash Flow | 6.60B |
| FCF Per Share | $4.18 |
Full Cash Flow StatementMargins
Gross margin is 65.52%, with operating and profit margins of 13.51% and 2.53%.
| Gross Margin | 65.52% |
| Operating Margin | 13.51% |
| Pretax Margin | 4.60% |
| Profit Margin | 2.53% |
| EBITDA Margin | 28.53% |
| EBIT Margin | 13.51% |
| FCF Margin | 23.18% |
Dividends & Yields
This stock pays an annual dividend of $0.53, which amounts to a dividend yield of 2.89%.
| Dividend Per Share | $0.53 |
| Dividend Yield | 2.89% |
| Dividend Growth (YoY) | 4.37% |
| Years of Dividend Growth | 1 |
| Payout Ratio | 117.40% |
| Buyback Yield | -0.25% |
| Shareholder Yield | 2.64% |
| Earnings Yield | 1.26% |
| FCF Yield | 11.55% |
Dividend DetailsAnalyst Forecast
| Price Target | n/a |
| Price Target Difference | n/a |
| Analyst Consensus | n/a |
| Analyst Count | n/a |
| Revenue Growth Forecast (5Y) | n/a |
| EPS Growth Forecast (5Y) | n/a |
Stock ForecastsFair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside | |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
Takeda Pharmaceutical has an Altman Z-Score of 1.08 and a Piotroski F-Score of 6. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 1.08 |
| Piotroski F-Score | 6 |
